{"id":49787,"date":"2022-10-19T12:02:04","date_gmt":"2022-10-19T10:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/"},"modified":"2022-10-19T12:02:04","modified_gmt":"2022-10-19T10:02:04","slug":"kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/","title":{"rendered":"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5648844\/kidney-cancer-drugs-market-by-therapy-by?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=2z392w&amp;utm_campaign=1764044+-+Kidney+Cancer+Drugs+Market+Global+Report+2022%3A+Increasing+Exposure+to+Cancer+Risk+Factors+Offers+Lucrative+Growth+Outlook&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg\"><\/a><\/p>\n<p>\nClear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure to cancer risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period.\n<\/p>\n<p>\nAccording to American Cancer Society&#8217;s January 2018 data findings, kidney cancer was among the 10 most common cancers in the U.S. in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer. Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to same source, around 9 out of 10 kidney cancers were renal cell carcinomas.\n<\/p>\n<p>\n<strong>Market Dynamics<\/strong>\n<\/p>\n<p>\nKey players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion, which would be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is in phase III stage.\n<\/p>\n<p>\n<strong>Key features of the study:<\/strong>\n<\/p>\n<ul>\n<li>\nThis report provides an in-depth analysis of the global kidney cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year\n<\/li>\n<li>\nIt elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market\n<\/li>\n<li>\nThis study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players\n<\/li>\n<li>\nIt profiles key players in the global kidney cancer drugs market based on the following parameters &#8211; company highlights, products portfolio, key highlights, financial performance, and strategies\n<\/li>\n<li>\nKey companies covered as a part of this study include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.\n<\/li>\n<li>\nInsights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics\n<\/li>\n<li>\nThe global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1\n<\/li>\n<li>\nStakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market\n<\/li>\n<\/ul>\n<p>\n<strong>Detailed Segmentation:<\/strong>\n<\/p>\n<p>\n<strong>Global Kidney Cancer Drugs Market, By Therapy:<\/strong>\n<\/p>\n<ul>\n<li>\nTargeted Therapy\n<\/li>\n<li>\nImmunotherapy\n<\/li>\n<li>\nChemotherapy\n<\/li>\n<\/ul>\n<p>\n<strong>Global Kidney Cancer Drugs Market, By Pharmacological Class:<\/strong>\n<\/p>\n<ul>\n<li>\nAngiogenesis Inhibitors\n<\/li>\n<li>\nmTOR Inhibitors\n<\/li>\n<li>\nCytokines\n<\/li>\n<li>\nOthers (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)\n<\/li>\n<\/ul>\n<p>\n<strong>Global Kidney Cancer Drugs Market, By Distribution Channel:<\/strong>\n<\/p>\n<ul>\n<li>\nHospital Pharmacies\n<\/li>\n<li>\nRetail Pharmacies\n<\/li>\n<li>\nOnline Pharmacies\n<\/li>\n<\/ul>\n<p>\n<strong>Global Kidney Cancer Drugs Market, By Region:<\/strong>\n<\/p>\n<ul>\n<li>\nNorth America\n<\/li>\n<li>\nBy Country\n<\/li>\n<li>\nU.S.\n<\/li>\n<li>\nCanada\n<\/li>\n<li>\nLatin America\n<\/li>\n<li>\nBy Country\n<\/li>\n<li>\nBrazil\n<\/li>\n<li>\nMexico\n<\/li>\n<li>\nArgentina\n<\/li>\n<li>\nRest of Latin America\n<\/li>\n<li>\nEurope\n<\/li>\n<li>\nBy Country\n<\/li>\n<li>\nGermany\n<\/li>\n<li>\nU.K.\n<\/li>\n<li>\nFrance\n<\/li>\n<li>\nItaly\n<\/li>\n<li>\nSpain\n<\/li>\n<li>\nRussia\n<\/li>\n<li>\nRest of Europe\n<\/li>\n<li>\nAsia Pacific\n<\/li>\n<li>\nBy Country\n<\/li>\n<li>\nChina\n<\/li>\n<li>\nIndia\n<\/li>\n<li>\nJapan\n<\/li>\n<li>\nAustralia\n<\/li>\n<li>\nSouth Korea\n<\/li>\n<li>\nASEAN\n<\/li>\n<li>\nRest of Asia Pacific\n<\/li>\n<li>\nMiddle East\n<\/li>\n<li>\nBy Country\n<\/li>\n<li>\nGCC\n<\/li>\n<li>\nIsrael\n<\/li>\n<li>\nRest of Middle East\n<\/li>\n<li>\nAfrica\n<\/li>\n<li>\nBy Region\/Country\n<\/li>\n<li>\nSouth Africa\n<\/li>\n<li>\nCentral Africa\n<\/li>\n<li>\nNorth Africa\n<\/li>\n<\/ul>\n<p>\n<strong>Company Profiles<\/strong>\n<\/p>\n<ul>\n<li>\nPfizer Inc\n<\/li>\n<li>\nNovartis International AG\n<\/li>\n<li>\nGenentech, Inc.\n<\/li>\n<li>\nActive Biotech AB\n<\/li>\n<li>\nAmgen Inc.\n<\/li>\n<li>\nBayer AG\n<\/li>\n<li>\nCipla Limited\n<\/li>\n<li>\nHoffmann-La Roche AG\n<\/li>\n<li>\nBristol-Myers Squibb Company\n<\/li>\n<li>\nEisai Co., Ltd.\n<\/li>\n<li>\nExelixis, Inc.\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Research Objectives and Assumptions<\/strong>\n<\/p>\n<p>\n<strong>2. Market Purview<\/strong>\n<\/p>\n<p>\n<strong>3. Market Dynamics, Regulations, and Trends Analysis<\/strong>\n<\/p>\n<p>\n<strong>4. Global Kidney Cancer Drugs Market- Impact of Coronavirus (Covid-19) Pandemic<\/strong>\n<\/p>\n<p>\n<strong>5. Global Kidney Cancer Drugs Market, By Therapy, 2017 &#8211; 2030, (US$ Billion)<\/strong>\n<\/p>\n<p>\n<strong>6. Global Kidney Cancer Drugs Market, By Pharmacologic Class, 2017 &#8211; 2030, (US$ Billion)<\/strong>\n<\/p>\n<p>\n<strong>7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2017 &#8211; 2030, (US$ Billion)<\/strong>\n<\/p>\n<p>\n<strong>8. Global Kidney Cancer Drugs Market, By Region, 2017 &#8211; 2030, (US$ Billion)<\/strong>\n<\/p>\n<p>\n<strong>9. Competitive Landscape<\/strong>\n<\/p>\n<p>\n<strong>10. Section<\/strong>\n<\/p>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5648844\/kidney-cancer-drugs-market-by-therapy-by?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=2z392w&amp;utm_campaign=1764044+-+Kidney+Cancer+Drugs+Market+Global+Report+2022%3A+Increasing+Exposure+to+Cancer+Risk+Factors+Offers+Lucrative+Growth+Outlook&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/u3ichr<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:press&#64;&#114;&#101;&#115;&#101;&#97;&#114;&#99;&#104;&#97;&#110;&#100;&#109;&#97;&#114;&#x6b;&#x65;&#x74;&#x73;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">p&#114;&#x65;&#x73;&#x73;&#64;&#114;&#x65;&#x73;&#x65;a&#114;&#x63;&#x68;&#x61;n&#100;&#x6d;&#x61;&#x72;k&#101;&#x74;&#x73;&#x2e;c&#111;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49787","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T10:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-10-19T10:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/\"},\"wordCount\":763,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005559\\\/en\\\/1606997\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/\",\"name\":\"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005559\\\/en\\\/1606997\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-10-19T10:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005559\\\/en\\\/1606997\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005559\\\/en\\\/1606997\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class, by Distribution Channel, and by Region &#8211; Size, Share, Outlook, and Opportunity Analysis, 2022 &#8211; 2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-19T10:02:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook &#8211; ResearchAndMarkets.com","datePublished":"2022-10-19T10:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/"},"wordCount":763,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/","name":"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg","datePublished":"2022-10-19T10:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221019005559\/en\/1606997\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kidney-cancer-drugs-market-global-report-2022-increasing-exposure-to-cancer-risk-factors-offers-lucrative-growth-outlook-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kidney Cancer Drugs Market Global Report 2022: Increasing Exposure to Cancer Risk Factors Offers Lucrative Growth Outlook &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49787"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49787\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}